/
Other
Dendritic Cell
14
Pipeline Programs↗
11
Active Trials↗
8
Companies Involved↗
Dendritic Cell is an emerging landscape with 14 programs across 8 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical2
Phase 14
Phase 28
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
75%
Small molecule
9 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.
Analysis
Trial Status
61
clinical trials
Completed29 · 48%
Terminated10 · 16%
Recruiting7 · 11%
Unknown status7 · 11%
Active, not recruiting4 · 7%
Withdrawn4 · 7%
Clinical Trials
Trial Activity
61 trials
Allogeneic Regulatory Dendritic Cell (DCreg) Renal Study
Active, not recruiting·—·Phase 1·NCT03726307·28 enrolled
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Active, not recruiting·—·Phase 1·NCT02159495·31 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)